PLoS ONE (Jan 2012)

Hepatitis B vaccine antibody response and the risk of clinical AIDS or death.

  • Michael L Landrum,
  • Katherine Huppler Hullsiek,
  • Robert J O'Connell,
  • Helen M Chun,
  • Anuradha Ganesan,
  • Jason F Okulicz,
  • Tahaniyat Lalani,
  • Amy C Weintrob,
  • Nancy F Crum-Cianflone,
  • Brian K Agan,
  • Infectious Disease Clinical Research Program HIV Working Group

DOI
https://doi.org/10.1371/journal.pone.0033488
Journal volume & issue
Vol. 7, no. 3
p. e33488

Abstract

Read online

BackgroundWhether seroresponse to a vaccine such as hepatitis B virus (HBV) vaccine can provide a measure of the functional immune status of HIV-infected persons is unknown.This study evaluated the relationship between HBV vaccine seroresponses and progression to clinical AIDS or death.Methods and findingsFrom a large HIV cohort, we evaluated those who received HBV vaccine only after HIV diagnosis and had anti-HBs determination 1-12 months after the last vaccine dose. Non-response and positive response were defined as anti-HBs ConclusionsHBV vaccine responses may have utility in assessing functional immune status and risk stratificating HIV-infected individuals, including those with CD4 count ≥ 500 cells/mm³.